Literature DB >> 10514520

CIS associates with the interleukin-2 receptor beta chain and inhibits interleukin-2-dependent signaling.

M J Aman1, T S Migone, A Sasaki, D P Ascherman, M h Zhu, E Soldaini, K Imada, A Miyajima, A Yoshimura, W J Leonard.   

Abstract

CIS is a cytokine-induced SH2-containing protein that was originally cloned as an interleukin (IL)-3-inducible gene. CIS is known to associate with the IL-3 receptor beta chain and erythropoietin receptor and to inhibit signaling mediated by IL-3 and erythropoietin. We now demonstrate that CIS also interacts with the IL-2 receptor beta chain (IL-2Rbeta). This interaction requires the A region of IL-2Rbeta (residues 313-382), which also mediates the association of IL-2Rbeta with Lck and Jak3. Correspondingly, CIS inhibits functions associated with both of these kinases: Lck-mediated phosphorylation of IL-2Rbeta and IL-2-mediated activation of Stat5. Thus, we demonstrate that CIS can negatively control at least two independent IL-2 signaling pathways. Although a functional SH2 binding domain of CIS was not required for its interaction with IL-2Rbeta in vitro, its phosphotyrosine binding capability was essential for the inhibitory action of CIS. On this basis, we have generated a mutant form of CIS protein with an altered SH2 domain that acts as a dominant negative and should prove useful in further understanding CIS action.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10514520     DOI: 10.1074/jbc.274.42.30266

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  28 in total

1.  Proteasomal regulation of betac signaling reveals a novel mechanism for cytokine receptor heterotypic desensitization.

Authors:  M Martinez-Moczygemba; D P Huston
Journal:  J Clin Invest       Date:  2001-12       Impact factor: 14.808

2.  CIS: the late-blooming eldest son.

Authors:  Akihiko Yoshimura
Journal:  Nat Immunol       Date:  2013-07       Impact factor: 25.606

Review 3.  Negative Regulation of Cytokine Signaling in Immunity.

Authors:  Akihiko Yoshimura; Minako Ito; Shunsuke Chikuma; Takashi Akanuma; Hiroko Nakatsukasa
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-07-02       Impact factor: 10.005

4.  Targeting cytokine signaling checkpoint CIS activates NK cells to protect from tumor initiation and metastasis.

Authors:  Eva M Putz; Camille Guillerey; Kevin Kos; Kimberley Stannard; Kim Miles; Rebecca B Delconte; Kazuyoshi Takeda; Sandra E Nicholson; Nicholas D Huntington; Mark J Smyth
Journal:  Oncoimmunology       Date:  2017-02-07       Impact factor: 8.110

5.  Unchaining NK cell-mediated anticancer immunosurveillance.

Authors:  Laurence Zitvogel; Guido Kroemer
Journal:  Nat Immunol       Date:  2016-06-21       Impact factor: 25.606

Review 6.  Suppression of cytokine signaling: the SOCS perspective.

Authors:  Edmond M Linossi; Jeffrey J Babon; Douglas J Hilton; Sandra E Nicholson
Journal:  Cytokine Growth Factor Rev       Date:  2013-03-30       Impact factor: 7.638

7.  SOCS proteins in development and disease.

Authors:  Monique C Trengove; Alister C Ward
Journal:  Am J Clin Exp Immunol       Date:  2013-02-27

8.  Negative cross-talk between interleukin-3 and interleukin-11 is mediated by suppressor of cytokine signalling-3 (SOCS-3).

Authors:  F Magrangeas; O Boisteau; S Denis; Y Jacques; S Minvielle
Journal:  Biochem J       Date:  2001-01-15       Impact factor: 3.857

9.  Intramolecular disulfide bonds of the prolactin receptor short form are required for its inhibitory action on the function of the long form of the receptor.

Authors:  Y-L Xie; S A Hassan; A M Qazi; C H Tsai-Morris; M L Dufau
Journal:  Mol Cell Biol       Date:  2009-03-09       Impact factor: 4.272

Review 10.  Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function.

Authors:  Douglas C Palmer; Nicholas P Restifo
Journal:  Trends Immunol       Date:  2009-10-30       Impact factor: 16.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.